6 completed. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 4 | Completed 4 |
Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation Evomela, Fludarabine, Total Body Irradiation - Hematological Malignancy, Multiple Myeloma | Phase 2 | Completed | Medical College of Wisconsin | 43 | 2017-12-08 | 2026-01-27 |
| Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®) - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Corewell Health West | 28 | 2012-04-01 | 2023-06-02 |
| A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy AlloStim - Hematological Malignancy, Leukemia | Phase 1 / Phase 2 | Completed | Mirror Biologics, Inc. | 6 | 2010-12-01 | 2020-01-22 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Isatuximab SAR650984, Dexamethasone - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Sanofi | 351 | 2010-05-11 | 2024-11-01 |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation donor lymphocyte infusion - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 11 | 2010-02-01 | 2013-01-14 |
| A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation reduced intensity conditionings - Allograft, Allogeneic Cell Transplantaion | Phase 2 | Completed | Institut Paoli-Calmettes | 148 | 2002-11-01 | 2014-01-01 |
Hematologic Neoplasms (6) · Multiple Myeloma (2) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Hematologic Diseases (5) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Disease Attributes (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2)
Bortezomib (1) · Cyclophosphamide (1) · Dexamethasone (1) · Melphalan (1) · Whole-Body Irradiation (1) · fludarabine (1) · fludarabine phosphate (1) · isatuximab (1)
Assistance Publique - Hôpitaux de Paris (1) · Corewell Health West (1) · Institut Paoli-Calmettes (1) · Medical College of Wisconsin (1) · Mirror Biologics, Inc. (1) · Sanofi (1)
France (3) · United States (3) · Israel (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Finland (1) · Greece (1) · Italy (1) · Mexico (1) · Peru (1) · Russia (1) · Spain (1) · Turkey (Türkiye) (1)
A. Samer Al-Homsi, MD (1) · Dr. Michael Har-Noy (1) · Mehdi Hamadani (1)